Corbus Pharmaceuticals (CRBP) Stock Forecast & Price Target

Compare

2,378 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRBP Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Corbus

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRBP Stock 12 Month Forecast

Average Price Target

$44.38

▲(423.97%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Corbus Pharmaceuticals in the last 3 months. The average price target is $44.38 with a high forecast of $58.00 and a low forecast of $28.00. The average price target represents a 423.97% change from the last price of $8.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","20":"$20","34":"$34","48":"$48","62":"$62"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$58.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,20,34,48,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.34,11.236923076923077,15.133846153846154,19.03076923076923,22.927692307692304,26.82461538461538,30.721538461538458,34.61846153846153,38.51538461538461,42.41230769230769,46.309230769230766,50.20615384615384,54.10307692307691,{"y":58,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.34,10.18923076923077,13.03846153846154,15.887692307692308,18.736923076923077,21.58615384615385,24.435384615384617,27.28461538461539,30.133846153846157,32.98307692307692,35.832307692307694,38.681538461538466,41.53076923076924,{"y":44.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.34,8.929230769230768,10.518461538461539,12.107692307692307,13.696923076923078,15.286153846153846,16.875384615384615,18.464615384615385,20.053846153846152,21.643076923076922,23.232307692307693,24.821538461538463,26.41076923076923,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.25,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.8,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.18,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.79,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$58.00

Average Price Target$44.38

Lowest Price Target$28.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Biren AminPiper Sandler

Piper Sandler

$35

Buy

313.22%

Upside

Reiterated

06/04/25

Piper Sandler Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Myriam BelghitiLifeSci Capital

LifeSci Capital

$53

Buy

525.74%

Upside

Reiterated

06/03/25

Corbus Pharmaceuticals: Strategic Positioning and Promising Pipeline Drive Buy Rating

Andres Y. MaldonadoH.C. Wainwright

H.C. Wainwright

$40

Buy

372.26%

Upside

Reiterated

06/02/25

Buy Rating for Corbus Pharmaceuticals' CRB-701: Promising Efficacy and Safety in Oncology

Graig SuvannavejhMizuho Securities

Mizuho Securities

$42→$32

Buy

277.80%

Upside

Reiterated

05/20/25

Mizuho Securities Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)

Kalpit PatelB.Riley Financial

B.Riley Financial

$40→$28

Buy

230.58%

Upside

Reiterated

05/07/25

Corbus Pharmaceuticals price target lowered to $28 from $40 at B. RileyCorbus Pharmaceuticals price target lowered to $28 from $40 at B. Riley

Brian AbrahamsRBC Capital

RBC Capital

$65→$58

Buy

584.77%

Upside

Reiterated

05/07/25

Corbus Pharmaceuticals price target lowered to $58 from $65 at RBC CapitalCorbus Pharmaceuticals price target lowered to $58 from $65 at RBC Capital

Jeff JonesOppenheimer

Oppenheimer

$60→$56

Buy

561.16%

Upside

Reiterated

05/07/25

Corbus Pharmaceuticals (CRBP) Receives a Buy from Oppenheimer

Andy HsiehWilliam Blair

William Blair

―

Buy

―

Reiterated

05/06/25

Analysts Are Bullish on These Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Beam Therapeutics (BEAM)

Maury RaycroftJefferies

Jefferies

$70→$53

Buy

525.74%

Upside

Reiterated

03/11/25

Analysts' Top Healthcare Picks: Lineage Therap (LCTX), Corbus Pharmaceuticals (CRBP)

Robert DriscollWedbush

Wedbush

$51

Buy

502.13%

Upside

Reiterated

02/07/25

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Biren AminPiper Sandler

Piper Sandler

$35

Buy

313.22%

Upside

Reiterated

06/04/25

Piper Sandler Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Myriam BelghitiLifeSci Capital

LifeSci Capital

$53

Buy

525.74%

Upside

Reiterated

06/03/25

Corbus Pharmaceuticals: Strategic Positioning and Promising Pipeline Drive Buy Rating

Andres Y. MaldonadoH.C. Wainwright

H.C. Wainwright

$40

Buy

372.26%

Upside

Reiterated

06/02/25

Buy Rating for Corbus Pharmaceuticals' CRB-701: Promising Efficacy and Safety in Oncology

Graig SuvannavejhMizuho Securities

Mizuho Securities

$42→$32

Buy

277.80%

Upside

Reiterated

05/20/25

Mizuho Securities Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)

Kalpit PatelB.Riley Financial

B.Riley Financial

$40→$28

Buy

230.58%

Upside

Reiterated

05/07/25

Corbus Pharmaceuticals price target lowered to $28 from $40 at B. RileyCorbus Pharmaceuticals price target lowered to $28 from $40 at B. Riley

Brian AbrahamsRBC Capital

RBC Capital

$65→$58

Buy

584.77%

Upside

Reiterated

05/07/25

Corbus Pharmaceuticals price target lowered to $58 from $65 at RBC CapitalCorbus Pharmaceuticals price target lowered to $58 from $65 at RBC Capital

Jeff JonesOppenheimer

Oppenheimer

$60→$56

Buy

561.16%

Upside

Reiterated

05/07/25

Corbus Pharmaceuticals (CRBP) Receives a Buy from Oppenheimer

Andy HsiehWilliam Blair

William Blair

―

Buy

―

Reiterated

05/06/25

Analysts Are Bullish on These Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Beam Therapeutics (BEAM)

Maury RaycroftJefferies

Jefferies

$70→$53

Buy

525.74%

Upside

Reiterated

03/11/25

Analysts' Top Healthcare Picks: Lineage Therap (LCTX), Corbus Pharmaceuticals (CRBP)

Robert DriscollWedbush

Wedbush

$51

Buy

502.13%

Upside

Reiterated

02/07/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Corbus Pharmaceuticals

1 Month

xxx

Success Rate

5/9 ratings generated profit

Average Return

+6.69%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +6.69% per trade.

3 Months

xxx

Success Rate

7/13 ratings generated profit

Average Return

+1.31%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +1.31% per trade.

1 Year

Andres Y. MaldonadoH.C. Wainwright

Success Rate

3/8 ratings generated profit

Average Return

-28.44%

reiterated a buy rating 4 days ago

Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -28.44% per trade.

2 Years

xxx

Success Rate

3/8 ratings generated profit

Average Return

-28.44%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -28.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRBP Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRBP has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRBP average Analyst price target in the past 3 months is 44.38.

Each month's total comprises the sum of three months' worth of ratings.

CRBP Financial Forecast

CRBP Earnings Forecast

Next quarter’s earnings estimate for CRBP is -$1.51 with a range of -$2.99 to -$0.89. The previous quarter’s EPS was -$1.39. CRBP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CRBP has Outperformed its overall industry.

CRBP Sales Forecast

Next quarter’s sales forecast for CRBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CRBP beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year CRBP has Preformed in-line its overall industry.

CRBP Stock Forecast FAQ

What is CRBP’s average 12-month price target, according to analysts?

Based on analyst ratings, Corbus Pharmaceuticals’s 12-month average price target is 44.38.

What is CRBP’s upside potential, based on the analysts’ average price target?

Corbus Pharmaceuticals has 423.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRBP a Buy, Sell or Hold?

Corbus Pharmaceuticals has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Corbus Pharmaceuticals’s price target?

The average price target for Corbus Pharmaceuticals is 44.38. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $58.00 ,the lowest forecast is $28.00. The average price target represents 423.97% Increase from the current price of $8.47.

What do analysts say about Corbus Pharmaceuticals?

Corbus Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of CRBP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Corbus Pharmaceuticals (CRBP) Stock Forecast & Price Target

CRBP Analyst Ratings

CRBP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Corbus Pharmaceuticals

CRBP Analyst Recommendation Trends

CRBP Financial Forecast

CRBP Earnings Forecast

CRBP Sales Forecast

CRBP Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts